Key Takeaways & Executive Findings
- •• Atezolizumab is associated with a spectrum of immune-related adverse events, with pneumonitis being the most frequently reported serious event. • Patients with non-small cell lung cancer (NSCLC) exhibit a higher risk of atezolizumab-induced pneumonitis compared to other tumor types. • Rare but severe adverse events such as myocarditis and myasthenia gravis were identified as potential safety signals. • The study underscores the necessity for proactive monitoring and management of immune-related toxicities in atezolizumab-treated patients.
Abstract
Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has been widely used in various malignancies. However, real-world adverse events (AEs) data are limited. This study aimed to comprehensively analyze AEs associated with atezolizumab using the FDA Adverse Event Reporting System (FAERS) and a pharmacovigilance database. We retrospectively analyzed AE reports from FAERS (2004-2023) and conducted disproportionality analysis using reporting odds ratio (ROR) and information component (IC). A total of 7,234 AE reports were identified, with 1,234 cases of serious AEs. The most common AEs included pneumonitis, hepatitis, colitis, thyroid dysfunction, and infusion-related reactions. Notably, we observed a higher risk of pneumonitis in patients with non-small cell lung cancer (NSCLC) compared to other cancers. Additionally, we identified potential safety signals for rare AEs such as myocarditis and myasthenia gravis. Our findings highlight the importance of vigilant monitoring for immune-related AEs, particularly in high-risk populations. This study provides valuable insights into the real-world safety profile of atezolizumab, supporting clinical decision-making and risk management.
1. Introduction
Atezolizumab, a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), has revolutionized cancer immunotherapy by enhancing T-cell-mediated antitumor responses. It has been approved for the treatment of various malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer, hepatocellular carcinoma, and urothelial carcinoma. Despite its clinical efficacy, immune checkpoint inhibitors (ICIs) are associated with a unique spectrum of immune-related adverse events (irAEs) resulting from nonspecific immune activation. These irAEs can affect any organ system, with the most common being dermatitis, colitis, hepatitis, and endocrinopathies. Although clinical trials have provided valuable safety data, real-world evidence is essential to capture the full range of AEs, especially rare and delayed toxicities that may not be detected in premarketing studies.
Pharmacovigilance databases, such as the FDA Adverse Event Reporting System (FAERS), serve as critical resources for postmarketing surveillance of drug safety. Disproportionality analysis of FAERS data enables the detection of potential safety signals by comparing the frequency of AEs for a specific drug against the background frequency of all other drugs. In this study, we conducted a comprehensive analysis of atezolizumab-associated AEs using FAERS data, aiming to characterize the safety profile, identify potential risk factors, and provide evidence for clinical monitoring and management strategies.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang, CHEN Jing (2025). Adverse Events Associated with Atezolizumab: A Comprehensive Analysis of the FDA Adverse Event Reporting System and Pharmacovigilance Database. Chinese Journal of New Drugs. https://doi.org/cast_zgxyzz_1236731783853699890
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is atezolizumab and how does it work?
Atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing the immune system's ability to attack cancer cells. It is used to treat various cancers, including non-small cell lung cancer and urothelial carcinoma.
What are the most common adverse events associated with atezolizumab?
The most common adverse events include fatigue, nausea, decreased appetite, and immune-related events such as pneumonitis, hepatitis, colitis, and thyroid dysfunction. Serious immune-related events can occur and require prompt management.
How was the safety data analyzed in this study?
We analyzed adverse event reports from the FDA Adverse Event Reporting System (FAERS) using disproportionality analysis methods such as reporting odds ratio (ROR) and information component (IC) to identify potential safety signals.
Are there any specific populations at higher risk for adverse events?
Our study found that patients with non-small cell lung cancer (NSCLC) may have a higher risk of atezolizumab-induced pneumonitis. Additionally, patients with pre-existing autoimmune diseases or those receiving combination therapies may be at increased risk.
What should clinicians do to manage immune-related adverse events?
Clinicians should monitor patients for signs and symptoms of immune-related adverse events, educate them about potential toxicities, and initiate appropriate management including corticosteroids or other immunosuppressive agents as needed. Early detection and intervention are crucial to prevent severe complications.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.